论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
外周血中性粒细胞与淋巴细胞比值在预测小细胞肺癌化疗结局中的临床意义
Received 22 October 2024
Accepted for publication 9 January 2025
Published 22 January 2025 Volume 2025:17 Pages 113—119
DOI https://doi.org/10.2147/CMAR.S502242
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Chien-Feng Li
Li Gao, Bin Liu
Department of Respiratory and Critical Care Medicine, Fuyang People’s Hospital, Fuyang, 236000, People’s Republic of China
Correspondence: Li Gao, Department of Respiratory and Critical Care Medicine, Fuyang People’s Hospital, No. 501, Sanqing Road, Qinghe Street, Yingzhou District, Fuyang, 236000, People’s Republic of China, Tel +86 0558-3010308, Email gaoliheibeu@126.com
Objective: This study aims to assess the clinical significance of the peripheral blood neutrophil-to-lymphocyte ratio (NLR) in predicting chemotherapy outcomes for patients with small cell lung cancer (SCLC).
Methods: A cohort of 44 patients diagnosed with SCLC between January 2021 to June 2022 at Fuyang People’s Hospital was selected for analysis. All patients in this group received a first-line platinum-based doublet chemotherapy regimen. In parallel, a control group consisting of 44 healthy individuals undergoing routine physical examinations at the same hospital was also selected. Fasting venous blood samples were collected in the morning within one week before the initiation of chemotherapy, and a complete blood cell count was performed to calculate the NLR.
Results: The NLR in the plasma of patients with SCLC was significantly elevated compared to that of healthy individuals (P < 0.01). After two cycles of chemotherapy, there were no statistically significant differences in plasma NLR in SCLC patients compared to pre-chemotherapy levels (P > 0.05). However, in the subgroup of patients with a partial response (PR) to treatment, the NLR decreased to 2.625 (95% CI: 1.900, 3.625), down from a pre-chemotherapy level of 3.430 (2.688, 4.800) (Z = − 3.127, P = 0.002). Conversely, in patients whose disease progressed (PD) following chemotherapy, the NLR increased to 3.880 (95% CI: 2.953, 5.223) from a pre-chemotherapy level of 2.060 (1.915, 2.968) (Z = − 2.521, P = 0.012).
Conclusion: The dynamic variations in the peripheral blood NLR before and after chemotherapy in patients with SCLC are strongly associated with the efficacy of first-line chemotherapy regimens. These changes in NLR levels may serve as a crucial indicator for predicting the effectiveness of first-line chemotherapy in patients with SCLC.
Keywords: chemotherapy effectiveness, efficacy prediction, inflammatory response, neutrophil-to-lymphocyte ratio, small cell lung cancer